|
Oncology Competitive Intelligence Leaders
Executive Summary: ONCrg analysts Kristen Cordova and Amber Mineo walk through the highest-impact lung cancer presentations from WCLC 2026 and preview what to watch at ESMO 2026 across small cell and non-small cell lung cancer, covering the context of each readout, how the treatment landscape is expected to shift, and the key questions the analyst team will be chasing.
Which mechanisms are commanding the late-breaker spotlight this year? Our analysts crunched the numbers across all LBAs:
ADCs lead the field — nearly a third of all LBA drugs, spanning NSCLC, breast, ovarian, and beyond.
Our oncology experts will be on the ground, analyzing the latest practice-changing clinical data, trial results, and emerging scientific insights as they unfold across over 20 tumor types.
Join our team as we break down the major readouts shaping thoracic oncology, including: 1L EGFR ex20ins+ NSCLC: First Phase III data for zipalertinib TKI-Naive ROS1+ NSCLC: Potentially registrational data for zidesamtinib 1L HER2m+ NSCLC: First Phase III data readout for T-DXd Relapsed SCLC: First CN Phase III data on two B7-H3 ADCs (tambotatug pelitecan […]
Excerpt from Custom Post Type Indication: CVAC
Excerpt from Custom Post Type Indication: ECS
ONCrg breast cancer analyst Carla Cabrera, PhD reviews five potentially practice-changing phase 3 readouts from ESMO 2025, spanning early HER2-positive breast cancer, first-line triple-negative disease, and…
Medical Conference Coverage EHA: June 11-14, 2026 WCLC: September 12-15, 2026 ESMO: October 23-27, 2026 SNO: November 12-15, 2026 SABCS: December 8-11, 2026 ASH: December 12-15, 2026 ASCO GU: February 11-13, 2027 ELCC: March 17-20, 2027 SGO: March 19-22, 2027 AACR: April 2-7, 2027 ASCO: June 4-8, 2027 ICML: June 15-19, 2027 Antibody-Drug Conjugates (ADCs) […]